Health House International Ltd. announced the launch of a non-interventional observational study in Germany considering the effect on quality of life of patients and the safety and tolerability of cannabis medication. The study has been launched by CanPharma (Germany) and supported by Kalapa Clinic (Germany/Spain), both 100% owned by Health House; with a focus on cannabis extracts and improving understanding and confidence of medical professionals in prescribing which are core parts of the Company?s growth strategy in the German market. The open, prospective, non-interventional study using CanPharma?s own-brand full spectrum cannabis extracts starts now and will run for a period of two years, with the first interim results expected in around 6 months. The analysis of data sets from up to 600 patients to be collected in the non-interventional study will support treatment safety as well as the ongoing improvement and standardisation of individualised cannabinoid therapy. The individual observation period for each participant is six months. CanPharma's observational study will be conducted at various centres in Germany. The observational study is being conducted by Kalapa Clinic, an independent part of the Health House group, whose medical experts have years of experience and in-depth expertise in cannabis therapy. Kalapa was the first medical cannabis counselling centre to be established in Europe. It advises health professionals and patients on the appropriate use of cannabis-based medicines for the treatment of various indications.